Genmab — November 2018
-
i første omgang vil jeg stille mig tilfreds med, at sc klarer safety - det er hurdlen for at komme til den egentlige fordel. Effektforbedringer vil være icing on the cake for mig
-
...men noget kan tyde på, at "molekyleniveauet" daler ved IV administration og SC rent faktisk giver en effektfordel. Det er sgu win-win
-
De vil nok forlange højere pris for SC, pga HALO skal have en bid auf kagen...
-
auf=af
-
Det har jeg svært ved at bedømme lige nu - der vil være en kæmpe volumenmæssig fordel i maintenance. Måske det kan modvirke en prisforhøjelse?
-
Cost+ prissætningen fungerer ikke altid
-
AMGN420 did start august 2015 https://clinicaltrials.gov/ct2/show/NCT02514239
-
https://ash.confex.com/ash/2018/webprogram/Paper109769.html and it looks like an car accident when you read it.
-
det er i hvert fald ikke en kur! hold da kæft
-
N=35 og kun 5 tilbage...
-
er det rigtigt at CR=6 på den baggrund?
-
@bulder, var det ikke AMGN420 du så som en konkurrent til Dara?? Ser sgu ikke sådan ud
-
eller husker jeg forkert?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind